隶属于 YALE UNIVERSITY
相关临床试验
2
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1810
进行中（未招募）
2
100.0%
暂无批准数据
- Ketamine, developed in the 1960s as a surgical anesthetic, has gained traction for treating depression, PTSD, and anxiety, spurring a wave of ketamine-therapy clinics across the U.S. - Dr. Gerard Sanacora of Yale School of Medicine warns that while ketamine has saved patients' lives, "these are truly dangerous drugs" that are not free of danger. - Extreme ketamine usage has been linked to neurotoxicity, cognition impairment, and bladder issues, underscoring the risks of unsupervised or recreational use. - The case of Katherine McCollough, who developed a ketamine addiction and died by suicide, highlights the dangers of promoting psychedelics outside clinical safeguards.
- Over half of individuals with opioid use disorder (OUD) in the United States also live with chronic pain, yet treatment for the two conditions is largely delivered in separate settings. - Yale's IMPOWR-YOU Center is running two core clinical trials—Pain CHAMP and SC-POWR—to evaluate integrated, single-setting care for co-occurring OUD and chronic pain. - Weill Cornell Medicine researchers are mapping health systems and analyzing the costs of emergency department-initiated buprenorphine to identify and address barriers to OUD care access. - Findings from five pilot studies and two clinical trials will be shared with the broader IMPOWR Research Network in early 2027 to inform future research and treatment.
- A Yale-led analysis of 51 intervention studies using DNA methylation-based epigenetic clocks found that lifestyle changes and certain drugs measurably slow biological aging, while over-the-counter supplements show little effect. - Pharmacologic interventions including metformin, semaglutide, and anti-TNF therapies decreased epigenetic age the most, with lifestyle changes such as diet plus exercise also consistently reducing biological age. - The study, published in Nature Medicine, measured more than 110 DNA methylation biomarkers and 16 major epigenetic clocks, showing newer biological age clocks outperform older models. - Researchers say validated biomarkers could let scientists evaluate anti-aging therapies in months or years rather than waiting decades for clinical trial evidence.
- Yale School of Medicine has launched a new online Master of Health Science in Medical AI, a two-year program designed for working professionals across clinical and technical tracks. - The program aims to bridge the persistent communication gap between clinicians and AI engineers, which has been identified as a major barrier to responsible AI adoption in medicine. - Students complete four core courses covering mathematical foundations, computational skills, medical context, and hands-on laboratory work, plus electives and a mentored capstone project. - Graduates are expected to fill emerging leadership roles such as chief medical AI officers, AI regulatory specialists, and machine learning scientists in healthcare systems and industry.
- A systematic review and meta-analysis of 36 studies found financial conflicts of interest exceed 50% prevalence across all six domains of the US oncology landscape examined. - Industry sponsorship was present in 69% of cancer clinical trials, and 61% of practicing oncologists received industry payments, with some domains reaching 100% prevalence. - Financial ties are associated with biased study design, pro-industry outcomes, higher prescribing of brand-name drugs, and sometimes less guideline-concordant care. - Researchers call for stronger transparency policies and safeguards to protect evidence integrity while acknowledging that industry collaboration remains essential to cancer research.
- Yale researchers identified mGluR4 and NPDC1 as critical transporters that carry misfolded α-synuclein into healthy neurons, revealing how Parkinson's disease spreads through the brain. - In mouse models, genetically removing either protein prevented toxic protein accumulation, reduced Parkinson's-like symptoms, and lowered the risk of death. - The study, published in Nature Communications, screened 4,400 cell surface proteins and found 16 that bind misfolded α-synuclein, with mGluR4 and NPDC1 confirmed as functional transporters. - Senior author Stephen Strittmatter says blocking this mechanism could lead to the first disease-slowing therapies, addressing a major unmet need for the 1.1 million Americans living with Parkinson's.
- Yale researchers discovered that mucosal IgA antibodies in the gut, not circulating IgG, are both necessary and sufficient for protection against norovirus infection in mouse models. - The study upends traditional vaccine strategies by demonstrating that CD8 T cells are not required for immunity, while B-cell-produced IgA is essential. - mRNA lipid nanoparticles engineered to produce anti-norovirus IgA completely protected mice from infection, opening a path to mRNA-based therapeutic strategies. - Norovirus causes 685 million cases and up to 200,000 deaths annually worldwide, yet no vaccines or antiviral drugs currently exist.
- Low-dose CT scans can reduce lung cancer-related mortality by 20%, with stage I survival rates above 70% compared to less than 10% for stage IV disease. - The USPSTF recommends annual LDCT screening for adults aged 50–80 with a 20-pack-year smoking history who currently smoke or quit within the last 15 years. - Lung cancer kills more women annually than breast, ovarian, and uterine cancers combined, yet screening awareness among eligible women remains low. - The noninvasive scan takes approximately 10 minutes, requires no contrast, fasting, or sedation, and can also detect cardiac abnormalities and upper abdominal findings.
- Perturb-DBiT enables spatially resolved CRISPR screening by co-sequencing sgRNAs and total RNA transcriptomes within intact tissue sections, preserving tumor architecture. - The method deployed over 80,000 sgRNAs across immune-competent and metastatic cancer models, linking genetic perturbations to RNA regulation and tumor-immune interactions. - Findings revealed how sgRNAs targeting genes like MT1E and S100A4 influence tumor proliferation and immune suppression in their native spatial context. - The technology challenges reliance on dissociation-based screens for IND-enabling studies, raising the evidentiary bar for mechanistic target validation in oncology.
- A Yale study published in JAMA found that 92% of 49 online websites prescribed GLP-1 medications to a fictitious patient profile, with 69% shipping the drugs directly. - Most websites sold compounded GLP-1 versions not FDA-reviewed or clinically tested, raising significant safety concerns about unregulated mass-marketed medications. - Researchers found prescriptions were often approved without any direct clinician communication, bypassing essential risk-benefit discussions and medical history verification. - The findings highlight urgent need for increased regulation, robust safeguards, and disclosure requirements for online telehealth platforms prescribing weight-loss medications.
